Key Highlights

  • Third-quarter 2026 net loss was USD 4.0 million, against USD 4.4 million.
  • Cash and short-term investments totaled USD 14.2 million at September 30, 2026.
  • The company requested an FDA Sprint Meeting on closing NEPHRO enrollment by December 31, 2026.
  • Management raised its peak annual U.S. sales estimate for Niyad above USD 200 million.

Talphera (NASDAQ:TLPH) reported third-quarter 2026 loss per share of USD 0.05, in line with the estimate of USD 0.05. The company reported no revenue. Its lead program is Niyad, an investigational nafamostat-based regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy, or CRRT.

The filing states that net loss was USD 4.0 million and USD 10.9 million for the three and nine months ended September 30, 2026, against USD 4.4 million and USD 10.5 million for the same periods of 2025.

Financial Results

The accumulated Deficit was USD 482.4 million at September 30, 2026, against USD 471.5 million at December 31, 2025. Cash and cash equivalents and short-term investments totaled USD 14.2 million, against USD 20.4 million at December 31, 2025.

Management said operating expenses, combining Research and Development and SG&A and excluding non-cash stock-based compensation, totaled USD 3.8 million for the third quarter, against USD 3.3 million. It attributed the USD 0.5 million increase primarily to higher Niyad development expenses and certain SG&A expenses related to pre-launch commercial preparation activities.

Net cash used in Operating Activities was USD 10,358 thousand for the nine months, against USD 8,928 thousand. Net cash provided by investing activities was USD 11,310 thousand, against cash used of USD 17,815 thousand, with USD 33.1 million in proceeds from sales and maturities of investments and USD 21.8 million in purchases of investments. Net cash provided by financing activities was USD 3,814 thousand, against USD 21,337 thousand, which in 2025 was primarily due to net proceeds from private placements in April and September 2025.

NEPHRO Study and FDA Request

Vincent Angotti, Chief Executive Officer, said the NEPHRO CRRT registrational study is being conducted in U.S. hospital ICUs. He said enrollment has exceeded 75% of the planned target and that enrollment in recent months has been slower due to fewer qualifying patients, noting that other CRRT studies have faced similar challenges. Management said the number of patients consented and enrolled dropped by 85% to 90% compared with the same period of 2025.

The company submitted a briefing document requesting an FDA Sprint Meeting to seek agreement to conclude enrollment by December 31, 2026 with the number of available patients enrolled at that time, instead of the originally planned target of 70 patients. Management said that, based on current enrollment, the study is over 80% powered for the primary endpoint. It said it would look for FDA feedback by the end of this year, and that topline data is targeted within four to six weeks after enrollment is completed.

Commercial Commentary

Management said it increased its estimate of Niyad's peak annual U.S. sales for use during CRRT to exceed USD 200 million, based on physician feedback from quantitative and qualitative research. It cited a New England Journal of Medicine study that compared CRRT with intermittent hemodialysis in critically ill patients with acute kidney injury and was stopped early after finding higher mortality among patients receiving intermittent hemodialysis. It also cited updated draft guidelines from KDIGO that include nafamostat as an alternative anticoagulant for CRRT when citrate cannot be used.